A shortage of isoniazid interfered with patient care and may contribute to the spread of tuberculosis in the United States, according to a report by the CDC. “Interruptions in the supply of second-line anti-TB medications have been ongoing in the United States for several years,” the researchers wrote in Morbidity and Mortality Weekly Report. “But since November 2012, TB control programs have experienced the first sustained generalized supply interruption of a first-line anti-TB medication.”
22 hours ago | Healio
Jasmine Grenier and Madhukar Pai from McGill University review “Spitting Blood: The History of Tuberculosis” by Helen Bynum.
16 May 2013 | PLoS Blogs (blog)
[Global Fund]Maseru, Lesotho -The Global Fund to Fight AIDS, Tuberculosis and Malaria announced today that it is signing two grant agreements with the Ministry of Finance of Lesotho totaling US$17 million, to allow Lesotho to expand prevention and treatment of HIV and multidrug resistant tuberculosis (MDR-TB).
09 May 2013 | AllAfrica
The report of the All-Party Group on Global Tuberculosis gives grounds for optimism; although the task is huge it provides a coherent set of recommendations that can be taken on by a new public health body seeking to demonstrate its leadership and effectiveness. Successfully leading the strategy to eliminate tuberculosis in the UK should be an agreed metric to measure the performance of Public Health England.
26 April 2013 | The Lancet (editorial)
An official said Wednesday that around 60 percent of HIV-infected people in Papua are known to have also suffered from tuberculosis (TB) and that up to 40 percent of TB patients in the province are also HIV-positive.
26 April 2013 | Jakarta Post
Antibiotic resistance is a global problem. The World Health Organisation (WHO) estimates that for tuberculosis alone multi-drug resistance accounts for more than 150,000 deaths each year. Now researchers are one step closer to understanding why antibiotics are ineffective against certain types of bacteria.
25 April 2013 | Durham University News
According to the new study, led by Harriet Mills at the University of Bristol, in communities that implement isoniazid preventive therapy (IPT), the incidence of new isoniazid-resistant cases per year will double in the next 40 years.
15 April 2013 | Nature
Sanofi-Aventis, manufacturer of the tuberculosis (TB) drug rifapentine (Priftin), can be credited for aiding research efforts to shorten and simplify treatment dosing for TB. However, the company’s pricing of the drug has hampered access to such regimens, even in resource-rich nations like the United States.
12 April 2013 | Treatment Action Group
TB mortality has decreased significantly since 2000 and treatment success rates have shown steady improvement. More than half of the countries that have received Global Fund support are on track to meet the international targets for case detection, treatment success, and TB disease incidence. However, multi-drug-resistant TB (MDR-TB) remains a critical threat.
09 April 2013 | Global Fund Observer
“Mine workers come from the whole sub-region to our mines to catch TB and HIV and take it back to their families and communities,” South African Minister of Health Dr. Aaron Motsoaledi said.
09 April 2013 | Inter Press Service